NYQUIL SINUS OTC
Generic Name and Formulations:
Acetaminophen 325mg, doxylamine succinate 6.25mg, phenylephrine HCl 5mg; per liquiCap.
Procter & Gamble Pharmaceuticals
Indications for NYQUIL SINUS:
Sinus pain, congestion, rhinorrhea, sneezing, headache.
2 caps every 4 hours; max 6 doses/24 hours.
During or within 14 days of MAOIs. Concomitant other acetaminophen products.
Hepatic dysfunction. Cardiovascular disease. Hypertension. GI or GU obstruction. Glaucoma. Thyroid disease. Diabetes. Asthma. Lower respiratory disorders. Pregnancy. Nursing mothers.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day; avoid. β-blockers increase pressor effects of sympathomimetics. Antagonizes antihypertensives. Increased CNS effects with other CNS depressants.
Analgesic + antihistamine + sympathomimetic.
Drowsiness, nervousness, dizziness, insomnia, anticholinergic effects, excitability in children, hepatotoxicity (overdosage).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Nicotinamide and Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML